Don't know who your advisor is, but as of Dec12 Missling did not yet have an answer to the first Biogen study. "A satisfactory result from the OPC assay study may lead to an in vivo remyelination study using a chemical demyelination model".
because of the holydays it might take a bit longer. AVXL might be also in talks with other BPs and one of them could comes on the board for ALZ or RETT in the near future.
for one of these deals AVXL will get upfront $40-60 million and 600-800 million in milestone payments. The partner will also pay for P3, if necessary.
Market Data 
Markets 
AI
